早期滤泡性淋巴瘤微小残留病监测可预测预后并指导放疗后利妥昔单抗治疗
该研究自2000年起纳入67例I/II期滤泡性淋巴瘤患者,采用PCR、RQ-PCR和ddPCR检测BCL2/IGH重排,所有患者接受累及野放疗(24-30 Gy),自2005年起放疗后MRD阳性者接受利妥昔单抗(375 mg/m2,每周4次)。中位随访82个月,诊断时72%患者BCL2/IGH阳性;放疗使50%患者转为MRD阴性;放疗后MRD阳性者中16/19(84%)经利妥昔单抗转为MRD阴性;
要点
- 诊断时循环BCL2/IGH+细胞低水平(<10^-5)及随访持续MRD阴性提示PFS更优。
- 标准累及野放疗仅使半数早期FL患者达到MRD阴性。
- 放疗后MRD阳性者接受利妥昔单抗大多可转阴,且PFS显著改善。
核心结论
- 早期滤泡性淋巴瘤诊断时循环BCL2/IGH+细胞水平及随访MRD状态具有预后意义。
- 标准累及野放疗不能使半数患者达到MRD阴性,放疗后MRD阳性者接受利妥昔单抗多可转阴并显著改善PFS。
研究设计与样本
- 自2000年起连续纳入67例I/II期滤泡性淋巴瘤患者,采用PCR、RQ-PCR和ddPCR检测BCL2/IGH重排。
- 所有患者接受累及野放疗(24-30 Gy),自2005年起放疗后MRD阳性者接受利妥昔单抗(375 mg/m2,每周4次)。
- 中位随访82个月(范围17-196个月)。
主要发现
- 诊断时72%患者为BCL2/IGH阳性。
- 累及野放疗使50%病例达到MRD阴性。
- 放疗后MRD阳性患者中16/19(84%)经利妥昔单抗治疗转为MRD阴性。
关键数值与推荐
- 累及野放疗剂量为24-30 Gy。
- 利妥昔单抗剂量为375 mg/m2,每周4次。
临床怎么用
- 对早期滤泡性淋巴瘤患者可检测诊断时循环BCL2/IGH+细胞水平以辅助预后分层。
- 放疗后监测MRD状态,MRD阳性者可考虑利妥昔单抗治疗以改善PFS。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since 2000, we have investigated 67 consecutive patients with stage I/II follicular lymphoma (FL) for the presence of BCL2/IGH rearrangements by polymerase chain reaction (PCR), real time quantitative PCR (RQ-PCR) and digital droplet PCR (ddPCR). All patients were treated with involved-field radiotherapy (IF-RT) (24-30 Gy). From 2005, patients with minimal residual disease (MRD) after IF-RT received rituximab (R) (375 mg/m2 , 4 weekly administrations). The median follow-up is 82 months (17-196). At diagnosis, 72% of patients were BCL2/IGH+. Progression-free survival (PFS) was significantly better in patients with undetectable/low levels (<10-5 ) of circulating BCL2/IGH+ cells at diagnosis and in those who were persistently MRD- during follow-up (P = 0·0038). IF-RT induced an MRD- status in 50% of cases; 16/19 (84%) MRD+ patients after IF-RT became MRD- after R treatment. A significantly longer PFS was observed in MRD+ patients treated with R compared to untreated MRD+ patients (P = 0·049). In early stage FL, both circulating levels of BCL2/IGH+ cells at diagnosis and MRD status during follow-up bear prognostic implications. Standard IF-RT fails to induce an MRD-negative status in half of patients. Most patients become MRD- following treatment with R and this is associated with a significantly better PFS.
引用
- Pulsoni A, Della Starza I, Cappelli LV, et al. Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy. Br J Haematol. 2019. PMID: 31385309. doi:10.1111/bjh.16125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。